Clinical Trial Update: Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis [Phase 2]

View source ↗

Summary

Phase 2 study assessing the efficacy, safety, and tolerability of CMK389 in chronic pulmonary sarcoidosis has completed enrollment and results were posted on 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis

Drugs mentioned

• CMK389

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Sarcoidosis | Phase 2 | Status: COMPLETED | Results posted: 2024-10-02